Intranigral/intrastriatal prostaglandin J2 injections in mice elicit dopaminergic neuronal loss, UB-aggregates and turning behavior

2007 ◽  
Vol 42 (1-2) ◽  
pp. 145
Author(s):  
S.B. Pierre ◽  
M.E. Figueiredo-Pereira
Keyword(s):  
Neuronal Loss ◽  
Turning Behavior ◽  
Dopaminergic Neuronal Loss ◽  
Prostaglandin J2

scholarly journals Curcumin inhibition of JNKs prevents dopaminergic neuronal loss in a mouse model of Parkinson’s disease through suppressing mitochondria dysfunction

2012 ◽  
Vol 1 (1) ◽  
pp. 16 ◽  
Author(s):  
Jing Pan ◽  
Hui Li ◽  
Jian-Fang Ma ◽  
Yu-Yan Tan ◽  
Qin Xiao ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Mouse Model ◽  
Neuronal Loss ◽  
Mitochondria Dysfunction ◽  
Dopaminergic Neuronal Loss

Aminochrome Induces Neuroinflammation and Dopaminergic Neuronal Loss: A New Preclinical Model to Find Anti-inflammatory and Neuroprotective Drugs for Parkinson’s Disease

2022 ◽  
Author(s):  
Fillipe Mendes De Araújo ◽  
Annyta Fernandes Frota ◽  
Lívia Bacelar de Jesus ◽  
Ticiane Caribe Macedo ◽  
Lorena Cuenca-Bermejo ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Neuronal Loss ◽  
Preclinical Model ◽  
Neuroprotective Drugs ◽  
Anti Inflammatory ◽  
Dopaminergic Neuronal Loss

Dopaminergic neuronal loss in transgenic mice expressing the Parkinson's disease-associated UCH-L1 I93M mutant

2007 ◽  
Vol 50 (1) ◽  
pp. 119-129 ◽  
Author(s):  
Rieko Setsuie ◽  
Yu-Lai Wang ◽  
Hideki Mochizuki ◽  
Hitoshi Osaka ◽  
Hideki Hayakawa ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Transgenic Mice ◽  
Neuronal Loss ◽  
Dopaminergic Neuronal Loss

An FP-CIT PET comparison of the difference in dopaminergic neuronal loss in subtypes of early Parkinson’s disease

2014 ◽  
Vol 55 (3) ◽  
pp. 366-371 ◽  
Author(s):  
In-Uk Song ◽  
Yong-An Chung ◽  
Jin-Kyoung Oh ◽  
Sung-Woo Chung
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Neuronal Loss ◽  
The Difference ◽  
Dopaminergic Neuronal Loss ◽  
Early Parkinson’S Disease

scholarly journals Chemical and Genetic Zebrafish Models to Define Mechanisms of and Treatments for Dopaminergic Neurodegeneration

2020 ◽  
Vol 21 (17) ◽  
pp. 5981
Author(s):  
Ola Wasel ◽  
Jennifer L. Freeman
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Neurodegenerative Diseases ◽  
Dopaminergic System ◽  
Neuronal Loss ◽  
Dopaminergic Neurodegeneration ◽  
Biological Studies ◽  
Vertebrate Model ◽  
Dopaminergic Neuronal Loss ◽  
6 Hydroxydopamine

The zebrafish (Danio rerio) is routinely used in biological studies as a vertebrate model system that provides unique strengths allowing applications in studies of neurodevelopmental and neurodegenerative diseases. One specific advantage is that the neurotransmitter systems are highly conserved throughout vertebrate evolution, including between zebrafish and humans. Disruption of the dopaminergic signaling pathway is linked to multiple neurological disorders. One of the most common is Parkinson’s disease, a neurodegenerative disease associated with the loss of dopaminergic neurons, among other neuropathological characteristics. In this review, the development of the zebrafish’s dopaminergic system, focusing on genetic control of the dopaminergic system, is detailed. Second, neurotoxicant models used to study dopaminergic neuronal loss, including 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), the pesticides paraquat and rotenone, and 6-hydroxydopamine (6-OHDA), are described. Next, zebrafish genetic knockdown models of dj1, pink1, and prkn established for investigating mechanisms of Parkinson’s disease are discussed. Chemical modulators of the dopaminergic system are also highlighted to showcase the applicability of the zebrafish to identify mechanisms and treatments for neurodegenerative diseases such as Parkinson’s disease associated with the dopaminergic system.

scholarly journals Relationship between microglial activation and dopaminergic neuronal loss in the substantia nigra: a time course study in a 6-hydroxydopamine model of Parkinson’s disease

2009 ◽  
Vol 110 (3) ◽  
pp. 966-975 ◽  
Author(s):  
Lilia Marinova-Mutafchieva ◽  
Mona Sadeghian ◽  
Lauren Broom ◽  
John B. Davis ◽  
Andrew D. Medhurst ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Substantia Nigra ◽  
Microglial Activation ◽  
Time Course ◽  
Neuronal Loss ◽  
Time Course Study ◽  
Dopaminergic Neuronal Loss ◽  
6 Hydroxydopamine

scholarly journals Intranasal insulin protects against substantia nigra dopaminergic neuronal loss and alleviates motor deficits induced by 6-OHDA in rats

Neuroscience ◽  
2016 ◽  
Vol 318 ◽  
pp. 157-165 ◽  
Author(s):  
Y. Pang ◽  
S. Lin ◽  
C. Wright ◽  
J. Shen ◽  
K. Carter ◽  
...  
Keyword(s):  
Substantia Nigra ◽  
Neuronal Loss ◽  
Motor Deficits ◽  
Intranasal Insulin ◽  
Dopaminergic Neuronal Loss
Sign in / Sign up

Export Citation Format

Share Document